272 Capital LP Buys New Position in Certara, Inc. (NASDAQ:CERT)

272 Capital LP purchased a new position in Certara, Inc. (NASDAQ:CERT) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 15,094 shares of the company’s stock, valued at approximately $177,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wasatch Advisors LP grew its stake in shares of Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after purchasing an additional 1,651,076 shares during the last quarter. Edgestream Partners L.P. bought a new stake in Certara during the third quarter worth approximately $1,782,000. Glenmede Trust Co. NA grew its position in Certara by 78.6% in the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after buying an additional 530,598 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Certara in the third quarter valued at $1,088,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of Certara during the 3rd quarter valued at $1,875,000. 73.96% of the stock is currently owned by institutional investors.

Insider Activity at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CERT shares. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. Finally, Barclays dropped their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.92.

Certara Price Performance

Shares of CERT opened at $11.21 on Friday. The business’s 50-day moving average is $10.81 and its 200-day moving average is $13.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -56.05, a P/E/G ratio of 5.70 and a beta of 1.51. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS. Equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.